Eric C. McGary, MD, PhD, MPH
Biography
Associate Professor
- Clinical Science
- Biomedical Science
Dr. Eric C. McGary serves as the Kaiser Permanente Bernard J. Tyson School of Medicine’s lead of Integrative Therapeutics, a role in which he helps develop and revise curriculum material for courses and clerkships as well as engages in small and large group facilitation. His research interests are precision and molecular medicine. He has developed a course in precision medicine and served as a research mentor for medical students at KPSOM and at Caltech. In addition to his roles at KPSOM, he is the Principal Investigator of the Kaiser Permanente Lung Cancer Clinical Trial Program and has served as an investigator on studies for the National Cancer Institute, cooperative group studies, and pharma sponsored studies.
Education and Training
- Degrees
-
BA,
Microbiology/Immunology, University of California, Berkeley
MD, Tulane University
PhD, Pharmacology/Molecular and Cellular Biology, Tulane University
MPH, Health Systems Management and Finance, Tulane University
- Internship
-
Internship and Residency,
The Scripps Clinic and Research Foundation
- Fellowship
-
Fellowship,
University of Texas M.D. Anderson Cancer Center
Professional Positions
- Faculty, Clinical Specialist
- University of Texas M.D. Anderson Cancer Center
- 2002-2003
- Clinical Assistant Professor
- Medical University of South Carolina
- 2003-2005
- Regional Lead
- National Beacon Collaborative Build Group
- 2007-Present
- Pharmacy and Therapeutic Committee
- Kaiser Permanente, West Los Angeles Region
- 2010-2018
- Chief, Section of Hematology and Oncology
- Kaiser Permanente, Southern California Region
- 2014-2020
- Medical Oncology Regional Lead, Thoracic Oncology Program
- Kaiser Permanente, Southern California Region
- 2017-2021
- Lead Director and PI, Lung Cancer Clinical Trials Research Program
- Kaiser Permanente, Southern California Region
- 2020-Present
- Associate Professor, Clinical Science
- Kaiser Permanente Bernard J. Tyson School of Medicine
- 2020-Present
- Associate Professor, Biomedical Science
- Kaiser Permanente Bernard J. Tyson School of Medicine
- 2020-Present
Honors and Awards
- National Westinghouse Science Scholar
- 1985
- Academic Merit Scholarship
- Wisconsin Academy of Sciences, University of Wisconsin-Madison
- 1985-1987
- Ciba-Geigy Award for Humanitarian Activity
- 1993
- Award for Doctoral Research
- American Cancer Society
- 1993
- Louisiana Superior Student Doctoral Stipend Award
- 1993-1995
- Travel Award
- American Society of Hematology
- 1995
- The Norman Rogers Cancer Award
- Tulane University School of Medicine, Tulane University Cancer Center
- 1997
- The 10th Annual Jorgen U. Schlegel Award
- Tulane University Graduate School
- 1997
- The John Taylor Halsey Award
- Tulane University School of Medicine
- 1997
Scholarly Activities
- Selected peer-reviewed research manuscripts
-
- McGary EC, Heimberger A, Mills L, Weber K, Thomas GW, Shtivelband M, Chelouche Lev DC, and Bar-Eli MA. Fully Human Antimelanoma Cellular Adhesion Molecule/MUC18 Antibody Inhibits Spontaneous Pulmonary Metastasis of Osteosarcoma Cells In Vivo. Clinical Cancer Research, 15;9(17):6560-6. 2003.
- McGary EC, Onn A, Mills L, Heimberger A, Thomas G, Shtivelband M, and Bar-Eli M. The Novel Tyrosine Kinase Inhibitor STI571 Inhibits PDGF Phosphorylation on Melanoma Cells but Does Not Affect Tumorgenicity In Vivo. Journal of Investigative Dermatology, 122, 400-405. 2004.
- Chelouche DL, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, McGary EC, Ananthaswamy HN, Price J, Bar-Eli M. Exposure of Melanoma Cells to Dacarbazine Results in Enhanced Tumor Growth and Metastasis In Vivo. Journal of Clinical Oncology, 22 (11), 2092- 2100. 2004.
- Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli, M. 2005. Loss of the AP-2a Transcription Factor is Associated with the Grade of Human Gliomas, Clinical Cancer Research, 11, 267-272. 2005.
- Heimberger AB, Wang E, McGary EC, Hess KR, Henry KV, Shono T, Cohen Z, Gumin J, Sawaya R, Conrad CA, Lang FF. Mechanisms of Action of Rapamycin in Gliomas. Neuro-Oncology, 7(1) 1-11. 2005.
- Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). Journal of Thoracic Oncology. 2019 Oct;14(10):1853-1859. doi: 10.1016/j.jtho.2019.06.027. Epub 2019 Jul 11.
- Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, Small EJ. Randomized Phase III Study of Enzalutamide Compared with Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Journal of Clinical Oncology. 2023 Mar 30: JCO2202394. doi: 10.1200/JCO.22.02394. Epub ahead of print. PMID: 36996380.
- Study of Enzalutamide Compared with Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Journal of Clinical Oncology. 2023 Mar 30: JCO2202394. doi: 10.1200/JCO.22.02394. Epub ahead of print. PMID: 36996380.
- Book Chapters
-
- McGary EC, Bedikian AY, Rapini RP. Malignant Melanoma: Biology, Diagnosis, and Management. M.D. Anderson Manual of Medical Oncology. H.M. Kantarjian, R.A. Wolff, C.A. Koller, eds. Chapter 32:855-877.
- Scandurro AB, McGary EC, Rondon IJ, Wilson RB, Beckman BS. Redox and Heat Shock Protein HSP70 Affect the Binding of Erythropoietin RNA Binding Protein to Erythropoietin mRNA. Molecular Biology of Hematopoiesis. NG Abraham, S Asano, G Brittinger, and R Shadduck, eds. Chapter 64:531-540.